Germline Genetic Predisposition to Hematologic Malignancy

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2017 Mar 16

PMID 28297620

Citations 47

Authors

Elissa Furutani

Akiko Shimamura

Affiliations

Soon will be listed here.

Abstract

Development of hematologic malignancies is driven by mutations that may be somatic or germline. Availability of next-generation DNA sequencing technologies has facilitated the development of individualized diagnostic evaluations and tailored treatment strategies. Until now, such personalized medical approaches have largely centered on prognostic stratification and treatment strategies informed by acquired somatic mutations. The role of germline mutations in children and adults with hematologic malignancies was previously underappreciated. Diagnosis of an inherited predisposition to hematologic malignancy informs choice of therapy, risk of treatment-related complications, donor selection for hematopoietic stem cell transplantation, evaluation of comorbidities, and surveillance strategies to improve clinical outcomes. The recognition that patients with inherited hematologic malignancy syndromes may present without classic clinical stigmata or suspicious family history has led to increased reliance on genetic testing, which, in turn, has raised new diagnostic challenges. Genomic testing is a rapidly evolving field with an increasing number of choices for testing for the practicing clinician to navigate. This review will discuss general approaches to diagnosis and management of patients with germline predisposition to hematology malignancies and will consider applications and limitations of genomic testing in clinical practice.

Citing Articles

Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts.

Hendricks R, Kim J, Haley J, Ramos M, Mirshahi U, Carey D Leukemia. 2024; 39(2):400-411.

PMID: 39501104 PMC: 11794151. DOI: 10.1038/s41375-024-02436-y.

Association of CTLA-4 polymorphisms with hematologic malignancy susceptibility: a meta-analysis.

Yan X, Zhang N, Wang G, Wang J Front Oncol. 2024; 14:1467740.

PMID: 39464701 PMC: 11502471. DOI: 10.3389/fonc.2024.1467740.

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?.

Le Calvez B, Jullien M, Dalle J, Renard C, Jubert C, Sterin A Hemasphere. 2024; 8(7):e120.

PMID: 38978638 PMC: 11229429. DOI: 10.1002/hem3.120.

Genomic testing for germline predisposition to hematologic malignancies.

Hwang S Blood Res. 2024; 59(1):12.

PMID: 38485837 PMC: 10923764. DOI: 10.1007/s44313-024-00012-y.

Editorial: Advances in predisposition to bone marrow failure and hematopoietic neoplasms.

Sahoo S, Abdelhamed S, Mochizuki-Kashio M, Wahlster L Front Oncol. 2024; 14:1377974.

PMID: 38434687 PMC: 10904646. DOI: 10.3389/fonc.2024.1377974.

References

DiNardo C, Bannon S, Routbort M, Franklin A, Mork M, Armanios M . Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016; 16(7):417-428.e2. PMC: 4925265. DOI: 10.1016/j.clml.2016.04.001. View

Malkin D . Li-Fraumeni Syndrome and p53 in 2015: Celebrating their Silver Anniversary. Clin Invest Med. 2016; 39(1):E37-47. DOI: 10.25011/cim.v39i1.26328. View

Muraoka M, Okuma C, Kanamitsu K, Ishida H, Kanazawa Y, Washio K . Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy. J Hum Genet. 2016; 61(6):523-6. DOI: 10.1038/jhg.2016.8. View

Similuk M, Rao V, Churpek J, Lenardo M . Predispositions to Lymphoma: A Practical Review for Genetic Counselors. J Genet Couns. 2016; 25(6):1157-1170. DOI: 10.1007/s10897-016-9979-0. View

Van Der Werff Ten Bosch J, van den Akker M . Genetic predisposition and hematopoietic malignancies in children: Primary immunodeficiency. Eur J Med Genet. 2016; 59(12):647-653. DOI: 10.1016/j.ejmg.2016.03.001. View

Zhang M, Churpek J, Keel S, Walsh T, Lee M, Loeb K . Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015; 47(2):180-5. PMC: 4540357. DOI: 10.1038/ng.3177. View

Kratz C, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U . Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer. 2015; 112(8):1392-7. PMC: 4402457. DOI: 10.1038/bjc.2015.75. View

Savage S, Bertuch A . The genetics and clinical manifestations of telomere biology disorders. Genet Med. 2010; 12(12):753-64. PMC: 3825100. DOI: 10.1097/GIM.0b013e3181f415b5. View

Carlsson G, Fasth A, Berglof E, Lagerstedt-Robinson K, Nordenskjold M, Palmblad J . Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/leukaemia. Br J Haematol. 2012; 158(3):363-9. DOI: 10.1111/j.1365-2141.2012.09171.x. View

10.

Smith M, Cavenagh J, Lister T, Fitzgibbon J . Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004; 351(23):2403-7. DOI: 10.1056/NEJMoa041331. View

11.

Sullivan K, Mullen C, Blaese R, Winkelstein J . A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994; 125(6 Pt 1):876-85. DOI: 10.1016/s0022-3476(05)82002-5. View

12.

Shah S, Schrader K, Waanders E, Timms A, Vijai J, Miething C . A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013; 45(10):1226-1231. PMC: 3919799. DOI: 10.1038/ng.2754. View

13.

Izraeli S, Vora A, Zwaan C, Whitlock J . How I treat ALL in Down's syndrome: pathobiology and management. Blood. 2013; 123(1):35-40. DOI: 10.1182/blood-2013-07-453480. View

14.

Dror Y, Donadieu J, Koglmeier J, Dodge J, Toiviainen-Salo S, Makitie O . Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann N Y Acad Sci. 2011; 1242:40-55. DOI: 10.1111/j.1749-6632.2011.06349.x. View

15.

Bannon S, DiNardo C . Hereditary Predispositions to Myelodysplastic Syndrome. Int J Mol Sci. 2016; 17(6). PMC: 4926372. DOI: 10.3390/ijms17060838. View

16.

Rosenberg P, Zeidler C, Bolyard A, Alter B, Bonilla M, Boxer L . Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010; 150(2):196-9. PMC: 2906693. DOI: 10.1111/j.1365-2141.2010.08216.x. View

17.

Stanley S, Gable D, Wagner C, Carlile T, Hanumanthu V, Podlevsky J . Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. Sci Transl Med. 2016; 8(351):351ra107. PMC: 5351811. DOI: 10.1126/scitranslmed.aaf7837. View

18.

Vlachos A, Muir E . How I treat Diamond-Blackfan anemia. Blood. 2010; 116(19):3715-23. PMC: 2981532. DOI: 10.1182/blood-2010-02-251090. View

19.

Ganly P, Walker L, Morris C . Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leuk Lymphoma. 2004; 45(1):1-10. DOI: 10.1080/1042819031000139611. View

20.

Spinner M, Sanchez L, Hsu A, Shaw P, Zerbe C, Calvo K . GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2013; 123(6):809-21. PMC: 3916876. DOI: 10.1182/blood-2013-07-515528. View